CYP2D6基因分型不应被用于确定绝经后乳腺癌患者的内分泌治疗方案。 - Suppr

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

作者信息

Rae J M

机构信息

Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA.

出版信息

Clin Pharmacol Ther. 2013 Aug;94(2):183-5. doi: 10.1038/clpt.2013.102.

DOI:10.1038/clpt.2013.102

PMID:23872830

Abstract

摘要

相似文献

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

Clin Pharmacol Ther. 2013 Aug;94(2):183-5. doi: 10.1038/clpt.2013.102.

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.

Clin Cancer Res. 2008 Sep 15;14(18):5913-8. doi: 10.1158/1078-0432.CCR-07-5235.

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.

Breast Cancer Res. 2005;7(3):R284-90. doi: 10.1186/bcr993. Epub 2005 Jan 28.

CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.

Clin Pharmacol Ther. 2013 Aug;94(2):185-7. doi: 10.1038/clpt.2013.66.

The ethics of CYP2D6 testing for patients considering tamoxifen.

Breast Cancer Res. 2007;9(2):103. doi: 10.1186/bcr1663.

CYP2D6 genotype and tamoxifen response.

Breast Cancer Res. 2005 Jul 29;7(5):E6. doi: 10.1186/bcr1297.

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22.

Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?

Pharmacol Res. 2016 May;107:398-406. doi: 10.1016/j.phrs.2016.03.025. Epub 2016 Apr 8.

Germline pharmacogenetics of tamoxifen response: have we learned enough?

J Clin Oncol. 2007 Nov 20;25(33):5147-9. doi: 10.1200/JCO.2007.13.4957.

The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.

Int J Cancer. 2018 Jul 1;143(1):184-189. doi: 10.1002/ijc.31291. Epub 2018 Feb 16.

引用本文的文献

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.

Clin Transl Sci. 2020 Mar;13(2):284-292. doi: 10.1111/cts.12707. Epub 2019 Nov 9.

An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

J Neural Transm (Vienna). 2019 Jan;126(1):5-18. doi: 10.1007/s00702-018-1922-0. Epub 2018 Sep 6.

Clinical Application of Pharmacogenetics: Where are We Now?

EJIFCC. 2013 Feb 21;24(3):105-12. eCollection 2013 Feb.

Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population.

Am J Transl Res. 2016 Aug 15;8(8):3585-92. eCollection 2016.

Endocrine resistance in breast cancer--An overview and update.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3(0 3):220-34. doi: 10.1016/j.mce.2015.09.035. Epub 2015 Oct 9.

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

Pharmacogenomics J. 2015 Feb;15(1):84-94. doi: 10.1038/tpj.2014.34. Epub 2014 Aug 5.

Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

J Natl Cancer Inst. 2014 Apr 3;106(5):dju063. doi: 10.1093/jnci/dju063.

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer.

Br J Clin Pharmacol. 2014 Aug;78(2):431-2. doi: 10.1111/bcp.12329.

Genomic medicine, precision medicine, personalized medicine: what's in a name?

Clin Pharmacol Ther. 2013 Aug;94(2):169-72. doi: 10.1038/clpt.2013.101.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献